rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-570-577rsp-3246Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESАнакинра в терапии болезни депонирования кристаллов пирофосфата кальция: опыт применения у 5 пациентов и обзор литературыThe use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature reviewhttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

115522, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-4383-9872ЧерёмушкинаЕ. В.CheremushkinaE. V.

Черёмушкина Елена Владимировна

115522, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

buipvybho@gmail.comhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Каширское шоссе, 34а

119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202225122022606570–577Copyright © Елисеев М.С., Черёмушкина Е.В., Насонов Е.Л., 20222022Елисеев М.С., Черёмушкина Е.В., Насонов Е.Л.Eliseev M.S., Cheremushkina E.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3246

Болезнь депонирования кристаллов пирофосфата кальция (БДПК) обусловлена их отложением в тканях, главным образом в суставном хряще, и часто проявляется развитием острого или хронического артрита. Терапия нестероидными противовоспалительными препаратами, колхицином, метотрексатом и глюкокортикоидами у этих пациентов нередко бывает неэффективной. В таких случаях рассматривается возможность назначения генно-инженерных биологических препаратов, прежде всего ингибиторов интерлейкина 1. В статье проанализирован опыт применения зарегистрированного в Российской Федерации в 2021 г. препарата анакинра, человеческого антагониста рецептора интерлейкина 1, у 5 пациентов с упорным течением артрита при БДПК. В статье также представлен анализ данных ключевых исследований по использованию препарата у пациентов с БДПК.

Calcium pyrophosphate crystal deposition disease (CPPD) is a disease caused by the deposition of calcium pyrophosphate crystals, mainly in the articular cartilage, and often manifests as severe acute or chronic arthritis. Therapy given in such cases with non-steroidal anti-inflammatory drugs, colchicine, methotrexate and glucocorticoids is often effective. In these cases, the possibility of prescribing biological drugs, primarily interleukin 1 (IL-1) inhibitors, is being considered. The article analyzes the experience of using Anakinra, an IL-1 receptor antagonist, registered in the Russian Federation in 2021, in 5 patients with persistent arthritis in CPPD. The article also presents an analysis of data from key studies on the use of the drug in patients with CPPD.

болезнь депонирования кристаллов пирофосфата кальцияанакинраcalcium pyrophosphate crystal deposition diseaseAnakinraИсследование выполнено в рамках прикладной темы «Оптимизация методов симптоматической противовоспалительной терапии у пациентов с микрокристаллическими артритами (подагра, болезнь депонирования кристаллов пирофосфата кальция)» № АААА-А20-120040190014-8.ReferencesКудаева ФМ, Владимиров СА, Елисеев МС, Волков АВ, Северинова МВ, Барскова ВГ. Особенности клинических проявлений болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2014;52(4):405-409. doi: 10.14412/1995-4484-2014-405-409Kudaeva FM, Vladimirov SA, Eliseev MS, Volkov AV, Severinova MV, Barskova VG. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(4):405-409 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409Hollander JL, Jessar RA, McCarty DJ. Synovianalysis: An aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-264.Hollander JL, Jessar RA, McCarty DJ. Synovianalysis: An aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-264.Черёмушкина ЕВ, Елисеев МС, Желябина ОВ. Поражение шейного отдела позвоночника при болезни депонирования кристаллов пирофосфата кальция (описание клинического случая). Современная ревматология. 2021;15(5):85-88. doi: 10.14412/1996-7012-2021-5-85-88Cheremushkina EV, Eliseev MS, Zhelyabina OV. Cervical vertebrae affection in calcium pyrophosphate crystal deposition disease (description of a clinical case). Modern Rheumatology Journal. 2021;15(5):85-88 (In Russ.)]. doi: 10.14412/1996-7012-2021-5-85-88Salcman M, Khan A, Symonds DA. Calcium pyrophosphate arthropathy of the spine: Case report and review of the literature. Neurosurgery. 1994;34(5):915-918;discussion 918. doi: 10.1227/00006123-199405000- 00022Salcman M, Khan A, Symonds DA. Calcium pyrophosphate arthropathy of the spine: Case report and review of the literature. Neurosurgery. 1994;34(5):915-918;discussion 918. doi: 10.1227/00006123-199405000- 00022Елисеев МС, Желябина ОВ, Чикина МН. Возрастные особенности болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2019;57(6):651-656. doi: 10.14412/1995-4484-2019-651-656Eliseev MS, Zhelyabina OV, Chikina MN. Age-related features of calcium pyrophosphate deposition disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(6): 651-656 (In Russ.) ]. doi: 10.14412/1995-4484-2019-651-656Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: A systematic review. Semin Arthritis Rheum. 2021;51(1):84-94. doi: 10.1016/j.semarthrit.2020.10.005Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: A systematic review. Semin Arthritis Rheum. 2021;51(1):84-94. doi: 10.1016/j.semarthrit.2020.10.005Stack J, McCarthy G. Calcium pyrophosphate deposition (CPPD) disease – Treatment options. Best Pract Res Clin Rheumatol. 2021;35(4):101720. doi: 10.1016/j.berh.2021.101720Stack J, McCarthy G. Calcium pyrophosphate deposition (CPPD) disease – Treatment options. Best Pract Res Clin Rheumatol. 2021;35(4):101720. doi: 10.1016/j.berh.2021.101720Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis. 2011;70(4):571-575. doi: 10.1136/ard.2010.139360Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis. 2011;70(4):571-575. doi: 10.1136/ard.2010.139360Cipolletta E, Di Matteo A, Scanu A, Isidori M, Di Battista J, Punzi L, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: A systematic literature review. Clin Exp Rheumatol. 2020;38(5):1001-1007.Cipolletta E, Di Matteo A, Scanu A, Isidori M, Di Battista J, Punzi L, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: A systematic literature review. Clin Exp Rheumatol. 2020;38(5):1001-1007.Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. doi: 10.1136/ard.2010.139105Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. doi: 10.1136/ard.2010.139105Guerne PA. Les mécanismes de l’inflammation microcristalline [Mechanisms of microcrystalline inflammation]. Rev Prat. 1994;44(2):161-166 (In French).Guerne PA. Les mécanismes de l’inflammation microcristalline [Mechanisms of microcrystalline inflammation]. Rev Prat. 1994;44(2):161-166 (In French).Macmullan P, McCarthy G. Treatment and management of pseudogout: Insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121-131. doi: 10.1177/1759720X11432559Macmullan P, McCarthy G. Treatment and management of pseudogout: Insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121-131. doi: 10.1177/1759720X11432559Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-609. [doi: 10.14412/1995-4484-2017-600-609Eliseev MS. Updated EULAR guidelines for the management of gout. Comments on certain items. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):600-609 (In Russ.)]. doi: 10.14412/1995-4484-2017-600-609McCarthy GM, Dunne A. Calcium crystal deposition diseases – Beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi: 10.1038/s41584-018-0078-5McCarthy GM, Dunne A. Calcium crystal deposition diseases – Beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi: 10.1038/s41584-018-0078-5Bouchard L, de Médicis R, Lussier A, Naccache PH, Poubelle PE. Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: Synergism with IL-1 to overexpress cyclooxygenase-2. J Immunol. 2002;168(10):5310-5317. doi: 10.4049/jimmunol.168.10.5310Bouchard L, de Médicis R, Lussier A, Naccache PH, Poubelle PE. Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: Synergism with IL-1 to overexpress cyclooxygenase-2. J Immunol. 2002;168(10):5310-5317. doi: 10.4049/jimmunol.168.10.5310Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: A time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 2002;46(4):961-967. doi: 10.1002/art.10212Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: A time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 2002;46(4):961-967. doi: 10.1002/art.10212Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: Implications for cartilage degradation in arthritis. Arthritis Rheum. 2006;54(10):3244-3253. doi: 10.1002/art.22167Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: Implications for cartilage degradation in arthritis. Arthritis Rheum. 2006;54(10):3244-3253. doi: 10.1002/art.22167Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther. 2003;5(2):94-103. doi: 10.1186/ar630Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther. 2003;5(2):94-103. doi: 10.1186/ar630Huang K, Wu LD. Aggrecanase and aggrecan degradation in osteoarthritis: A review. J Int Med Res. 2008;36(6):1149-1160. doi: 10.1177/147323000803600601Huang K, Wu LD. Aggrecanase and aggrecan degradation in osteoarthritis: A review. J Int Med Res. 2008;36(6):1149-1160. doi: 10.1177/147323000803600601Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;68(10):1602-1608. doi: 10.1136/ard.2009.109355Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;68(10):1602-1608. doi: 10.1136/ard.2009.109355Pawelek SA, Illes JD, Taylor JA. Calcium pyrophosphate dihydrate crystal deposition disease simulating osteoarthrosis of the knee: A case report. J Chiropr Med. 2016;15(3):219-223. doi: 10.1016/j.jcm.2016.04.005Pawelek SA, Illes JD, Taylor JA. Calcium pyrophosphate dihydrate crystal deposition disease simulating osteoarthrosis of the knee: A case report. J Chiropr Med. 2016;15(3):219-223. doi: 10.1016/j.jcm.2016.04.005Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi: 10.14412/1995-4484-2016-60-77Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1): 60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77Елисеев МС, Насонов ЕЛ. Применение канакинумаба при подагре. Научно-практическая ревматология. 2018;56:41-48. doi: 10.14412/1995-4484-2018-41-48Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56:41-48 (In Russ.)]. doi: 10.14412/1995-4484-2018-41-48Yashiro T, Okamoto T, Tanaka R, Ito K, Hara H, Yamashita T, et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. Endocrinol Jpn. 1991;38(5):457-464. doi: 10.1507/endocrj1954.38.457Yashiro T, Okamoto T, Tanaka R, Ito K, Hara H, Yamashita T, et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. Endocrinol Jpn. 1991;38(5):457-464. doi: 10.1507/endocrj1954.38.457Ramonda R, Musacchio E, Perissinotto E, Sartori L, Punzi L, Corti MC, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27(6):981-984.Ramonda R, Musacchio E, Perissinotto E, Sartori L, Punzi L, Corti MC, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27(6):981-984.Kleiber Balderrama C, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium pyrophosphate deposition disease and associated medical comorbidities: A national cross-sectional study of US veterans. Arthritis Care Res (Hoboken). 2017;69(9):1400-1406. doi: 10.1002/acr.23160Kleiber Balderrama C, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium pyrophosphate deposition disease and associated medical comorbidities: A national cross-sectional study of US veterans. Arthritis Care Res (Hoboken). 2017;69(9):1400-1406. doi: 10.1002/acr.23160Altomare A, Corrado A, Maruotti N, Cici D, Cantatore FP. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021;48(5):4789-4796. doi: 10.1007/s11033-021-06457-zAltomare A, Corrado A, Maruotti N, Cici D, Cantatore FP. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021;48(5):4789-4796. doi: 10.1007/s11033-021-06457-zMcGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58(2):631-633. doi: 10.1002/art.23119McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58(2):631-633. doi: 10.1002/art.23119Moltó A, Ea HK, Richette P, Bardin T, Lioté F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79(6):621-623. doi: 10.1016/j.jbspin.2012.01.010Moltó A, Ea HK, Richette P, Bardin T, Lioté F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79(6):621-623. doi: 10.1016/j.jbspin.2012.01.010Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature. Joint Bone Spine. 2013;80(2):178-182. doi: 10.1016/j.jbspin.2012.07.018Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature. Joint Bone Spine. 2013;80(2):178-182. doi: 10.1016/j.jbspin.2012.07.018Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345-1349. doi: 10.3899/jrheum.181018Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345-1349. doi: 10.3899/jrheum.181018Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled doubleblinded pilot study. Joint Bone Spine. 2021;88(2):105088. doi: 10.1016/j.jbspin.2020.105088Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, AubryRozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled doubleblinded pilot study. Joint Bone Spine. 2021;88(2):105088. doi: 10.1016/j.jbspin.2020.105088Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: Report of three cases. Joint Bone Spine. 2012;79(3):330-331. doi: 10.1016/j.jbspin.2011.12.017Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: Report of three cases. Joint Bone Spine. 2012;79(3):330-331. doi: 10.1016/j.jbspin.2011.12.017Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18(6):310-311. doi: 10.1097/RHU.0b013e31826149a2Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18(6):310-311. doi: 10.1097/RHU.0b013e31826149a2Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystalinduced arthritis in complex hospitalized patients: A case series and review of the literature. Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystalinduced arthritis in complex hospitalized patients: A case series and review of the literature. Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Pazár B, Ea HK, Narayan S, Kolly L, Bagnoud N, Chobaz V, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immu nol. 2011;186(4):2495-2502. doi: 10.4049/jimmunol.1001284Pazár B, Ea HK, Narayan S, Kolly L, Bagnoud N, Chobaz V, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immu nol. 2011;186(4):2495-2502. doi: 10.4049/jimmunol.1001284Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. doi: 10.1155/2015/194864Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. doi: 10.1155/2015/194864Ahmed HMA, Sun D, Gaffo A. Factors affecting response to anakinra in crystalline arthritis flares. J Clin Rheumatol. 2022;28(4):196-200. doi: 10.1097/RHU.0000000000001831Ahmed HMA, Sun D, Gaffo A. Factors affecting response to anakinra in crystalline arthritis flares. J Clin Rheumatol. 2022;28(4):196-200. doi: 10.1097/RHU.0000000000001831Liebner R, Mathaes R, Meyer M, Hey T, Winter G, Besheer A. Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra. Eur J Pharm Biopharm. 2014;87(2):378-385. doi: 10.1016/j.ejpb.2014.03.010Liebner R, Mathaes R, Meyer M, Hey T, Winter G, Besheer A. Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra. Eur J Pharm Biopharm. 2014;87(2):378-385. doi: 10.1016/j.ejpb.2014.03.010

The authors declare that there are no conflicts of interest present.